India, Sept. 8 -- Several biotech stocks were in focus Tuesday, including Bluejay Diagnostics following a federal healthcare partnership with Lovell Government Services; Pharvaris after positive Phase 3 CHAPTER-3 results; Roivant following positive Phase 2 PHocus data; PDS Biotech after announcing up to $22.55 million in PIPE financing led by Nant Capital; and Atara Biotherapeutics after an update on the anticipated resubmission of its tabelecleucel BLA.
Read on.
Bluejay Diagnostics (BJDX) announced a distribution, co-marketing and strategic partnership with Lovell Government Services to expand access to U.S. federal healthcare markets, pending FDA clearance. Under the agreement, Lovell will serve as Bluejay's exclusive distributor for fe...